Ikaria Inc.

Ikaria Inc. is a biotechnology company that focuses on developing and commercializing innovative therapies for critically ill patients, particularly those in the Intensive Care Unit (ICU) and Cardiac Care Unit (CCU). The company was founded in 2004 by Baxter International and Morgan Stanley, with the goal of addressing the unmet medical needs of patients with life-threatening conditions, such as Sepsis, Acute Respiratory Distress Syndrome (ARDS), and Cardiac Arrest. Ikaria Inc. has collaborated with various organizations, including the National Institutes of Health (NIH), Food and Drug Administration (FDA), and European Medicines Agency (EMA), to advance its research and development efforts. The company's work has also been supported by investments from Venture Capital firms, such as New Enterprise Associates (NEA) and Arch Venture Partners.

● History

Ikaria Inc. was established in 2004, with its headquarters in Hampton, New Jersey, and has since become a leading player in the biotechnology industry, with a focus on developing therapies for critically ill patients. The company's founders, including Baxter International and Morgan Stanley, brought together a team of experienced professionals from the Biotechnology Industry, including Genentech, Amgen, and Johnson & Johnson. Ikaria Inc. has also partnered with various academic institutions, such as Harvard University, Stanford University, and University of California, San Francisco (UCSF), to advance its research and development efforts. The company's history is marked by significant milestones, including the completion of its Initial Public Offering (IPO) in 2007, and its subsequent acquisition by Mallinckrodt Pharmaceuticals in 2015.

● Products and Services

Ikaria Inc. has developed a range of products and services focused on addressing the unmet medical needs of critically ill patients, including its flagship product, INOMAX (nitric oxide), which is used to treat Persistent Pulmonary Hypertension of the Newborn (PPHN) and other respiratory conditions. The company has also developed other products, such as Biotherapeutics and Small Molecules, which are designed to treat a range of conditions, including Sepsis, Acute Kidney Injury (AKI), and Cardiac Arrest. Ikaria Inc.'s products have been approved by regulatory agencies, including the Food and Drug Administration (FDA) and European Medicines Agency (EMA), and have been used in hospitals and Intensive Care Units (ICUs) around the world, including Massachusetts General Hospital, University of California, Los Angeles (UCLA), and University of Oxford.

● Research and Development

Ikaria Inc. has a strong commitment to research and development, with a focus on developing innovative therapies for critically ill patients. The company has established partnerships with various academic institutions, including Harvard University, Stanford University, and University of California, San Francisco (UCSF), to advance its research efforts. Ikaria Inc. has also collaborated with other biotechnology companies, such as Genentech, Amgen, and Biogen Idec, to develop new therapies and technologies. The company's research and development efforts have been supported by investments from Venture Capital firms, such as New Enterprise Associates (NEA) and Arch Venture Partners, and have resulted in the development of several promising therapies, including INOMAX (nitric oxide) and other Biotherapeutics and Small Molecules.

● Financial Information

Ikaria Inc. has received significant investments from Venture Capital firms, including New Enterprise Associates (NEA) and Arch Venture Partners, and has also generated revenue through the sale of its products, including INOMAX (nitric oxide). The company's financial performance has been impacted by various factors, including the Global Financial Crisis and changes in the Biotechnology Industry. Ikaria Inc. has also been involved in several significant transactions, including its acquisition by Mallinckrodt Pharmaceuticals in 2015, and has reported financial results to the Securities and Exchange Commission (SEC). The company's financial information has been audited by accounting firms, including Deloitte and PricewaterhouseCoopers (PwC), and has been reviewed by regulatory agencies, including the Food and Drug Administration (FDA) and European Medicines Agency (EMA).

● Management and Leadership

Ikaria Inc. has been led by a team of experienced professionals, including its former Chief Executive Officer (CEO), Daniel Tasse, and its former Chief Financial Officer (CFO), Robert Cobuzzi. The company's management team has included individuals with experience in the Biotechnology Industry, including Genentech, Amgen, and Johnson & Johnson. Ikaria Inc. has also been advised by a board of directors, including Morgan Stanley and Baxter International, and has established partnerships with various academic institutions, including Harvard University, Stanford University, and University of California, San Francisco (UCSF). The company's leadership has been recognized through various awards, including the Ernst & Young Entrepreneur of the Year Award and the Biotechnology Industry Organization (BIO) Chairman's Award. Category:Biotechnology companies